The role of adiponectin gene variants in glycemic control in patients with Type 2 diabetes

Endocrine Research

Volumn 39, Issue 1, 2014, Pages 13-17

  Al Azzam, Sayer I ^a   Khabour, Omar F ^a   Alzoubi, Karem H ^a   Mukattash, Tareq L ^a   Ghanma, Mais ^a   Saleh, Hanan ^a  

^a JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

Author keywords

Adiponectin; Genotype; Glycemic control; Insulin resistance; SNPs; Type II diabetes

Indexed keywords

ADIPONECTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID;

ARTICLE; FEMALE; GENETIC VARIABILITY; GENOTYPE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

ADIPONECTIN; ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LEPTIN; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 84892726485     PISSN: 07435800     EISSN: None     Source Type: Journal    
DOI: 10.3109/07435800.2013.794427     Document Type: Article

References (33)

1. Shogbon AO, Levy SB. Intensive glucose control in the management of diabetes mellitus and inpatient hyperglycemia. Am J Health Syst Pharm 2010;67: 798-805.
2. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329: 977-86.
3. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2007;30:S42-7.
4. Sheng T, Yang K. Adiponectin and its association with insulin resistance and type 2 diabetes. J Genet Genomics 2008;35: 321-6.
5. Kawano J, Arora R. The role of adiponectin in obesity, diabetes, and cardiovascular disease. J Cardiometab Syndr 2009;4: 44-9.
6. Li S, Shin HJ, Ding EL, et al. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009;302: 179-88.
7. Schwarz PE, Towers GW, Fischer S, et al. Hypoadiponectinemia is associated with progression toward type 2 diabetes and genetic variation in the ADIPOQ gene promoter. Diabetes Care 2006;29: 1645-50.
8. Duncan BB, Schmidt MI, Pankow JS, et al. Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2004;53: 2473-8.
9. Ravussin E. Adiponectin enhances insulin action by decreasing ectopic fat deposition. Pharmacogenomics J 2002;2: 4-7.
10. Kissebah AH, Sonnenberg GE, Myklebust J, et al. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci USA 2000;97: 14478-83.
11. Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001;86: 3815-9.
12. Hara K, Boutin P, Mori Y, et al. Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 2002;51: 536-40.
13. Gable DR, Hurel SJ, Humphries SE. Adiponectin and its gene variants as risk factors for insulin resistance, the metabolic syndrome and cardiovascular disease. Atherosclerosis 2006;188: 231-44.
14. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012;35:S64-71.
15. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24: 67-74.
16. Toobert DJ, Hampson SE, Glasgow RE. The summary of diabetes self-care activities measure: results from 7 studies and a revised scale. Diabetes Care 2000;23: 943-50.
17. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28: 412-9.
18. Bonora E, Formentini G, Calcaterra F, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 2002;25: 1135-41.
19. Khabour OF, Mesmar FS, Alatoum MA, et al. Associations of polymorphisms in adiponectin and leptin genes with men's longevity. Aging Male 2010;13: 188-93.
20. Sanghera DK, Demirci FY, Been L, et al. PPARG and ADIPOQ gene polymorphisms increase type 2 diabetes mellitus risk in Asian Indian Sikhs: Pro12Ala still remains as the strongest predictor. Metabolism 2010;59: 492-501.
21. Schwarz PE, Govindarajalu S, Towers W, et al. Haplotypes in the promoter region of the ADIPOQ gene are associated with increased diabetes risk in a German Caucasian population. Horm Metab Res 2006;38: 447-51.
22. Gong M, Long J, Liu Q, et al. Association of the ADIPOQ rs17360539 and rs266729 polymorphisms with type 2 diabetes: a meta-analysis. Mol Cell Endocrinol 2010;325: 78-83.
23. Siitonen N, Pulkkinen L, Lindstrom J, et al. Association of ADIPOQ gene variants with body weight, type 2 diabetes and serum adiponectin concentrations: the Finnish Diabetes Prevention Study. BMC Med Genet 2011;12:5.
24. Jing C, Xueyao H, Linong J. Meta-analysis of association studies between five candidate genes and type 2 diabetes in Chinese Han population. Endocrine 2012;42: 307-20.
25. Lacquemant C, Froguel P, Lobbens S, et al. The adiponectin gene SNP+45 is associated with coronary artery disease in Type 2 (noninsulin- dependent) diabetes mellitus. Diabet Med 2004;21: 776-81.
26. Bacci S, Menzaghi C, Ercolino T, et al. The +276 G/T single nucleotide polymorphism of the adiponectin gene is associated with coronary artery disease in type 2 diabetic patients. Diabetes Care 2004;27: 2015-20.
27. Vasseur F, Helbecque N, Lobbens S, et al. Hypoadiponectinaemia and high risk of type 2 diabetes are associated with adiponectinencoding (ACDC) gene promoter variants in morbid obesity: evidence for a role of ACDC in diabesity. Diabetologia 2005;48: 892-9.
28. Long AN, Dagogo-Jack S. Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection. J Clin Hypertens (Greenwich) 2011;13: 244-51.
29. Ma J, Yang W, Fang N, et al. The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: a meta-analysis. Nutr Metab Cardiovasc Dis 2009;19: 596-603.
30. Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005;28: 956-62.
31. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49: 1711-21.
32. Okada K, Maeda N, Kikuchi K, et al. Pravastatin improves insulin resistance in dyslipidemic patients. J Atheroscler Thromb 2005;12: 322-9.
33. Sasaki J, Iwashita M, Kono S. Statins: beneficial or adverse for glucose metabolism. J Atheroscler Thromb 2006;13: 123-9.